Ocugen Inc (OCGN)

02:35 AM

Ocugen Inc (OCGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

02:35 AM

01:31 AM

OCGN|Ocugen Inc|Price:1.262|Chg%:+0.051 - TradingKey

01:31 AM

12:45 PM

Ocugen Inc (OCGN) Valuation: PE, PB & Fair Value Analysis - TradingKey

12:45 PM

Jul 27, 2026

Ocugen Inc (OCGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 27, 2026

Jul 27, 2026

Ocugen Inc (OCGN) Cash Flow - TradingKey

Jul 27, 2026

Jul 27, 2026

Ocugen Inc (OCGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026

Jul 27, 2026

Ocugen Inc (OCGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026

Jul 27, 2026

Ocugen Inc (OCGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026

Jul 25, 2026

Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout | AI

Jul 25, 2026

Jul 25, 2026

Ocugen Inc (OCGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks

Jul 25, 2026

Jul 25, 2026

OCGN|Ocugen Inc|Price:1.210|Chg%:-0.060 - TradingKey

Jul 25, 2026

Jul 25, 2026

Ocugen Inc (OCGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 25, 2026

Jul 25, 2026

Ocugen Inc (OCGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 25, 2026

Jul 25, 2026

Ocugen Inc (OCGN) Institutional Confidence - TradingKey

Jul 25, 2026

Jul 24, 2026

Ocugen Inc. stock falls Friday, underperforms market - MarketWatch

Jul 24, 2026

Jul 24, 2026

Ocugen, Inc. targets next generation brain gene therapies with new delivery approaches - Traders Union

Jul 24, 2026

Jul 24, 2026

OCGN Q2'26 Earnings: revenue estimate is 976.14K USD - TradingView

Jul 24, 2026

Jul 24, 2026

Ocugen (OCGN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat

Jul 24, 2026

Jul 23, 2026

Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch

Jul 23, 2026

Jul 22, 2026

Why Did OCGN Stock Rise Today? - Stocktwits

Jul 22, 2026

Jul 22, 2026

OCGN stock holds attention as Ocugen updates its pipeline - AD HOC NEWS

Jul 22, 2026

Jul 21, 2026

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Jul 21, 2026

Jul 20, 2026

Ocugen (OCGN) targets 250M-share authorization increase tied to $130M converts - Stock Titan

Jul 20, 2026

Jul 20, 2026

Ocugen Inc. stock falls Monday, underperforms market - MarketWatch

Jul 20, 2026

Jul 20, 2026

Ocugen (OCGN) Proxy filing Summary - Quartr

Jul 20, 2026

Jul 19, 2026

Ocugen Targets $259 Million in MENA Licensing Deal for OCU400 - MyChesCo

Jul 19, 2026

Jul 15, 2026

OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits

Jul 15, 2026

Jul 14, 2026

Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch

Jul 14, 2026

Jul 14, 2026

Ocugen licenses gene therapy to Roots Pharmaceutica - BioXconomy

Jul 14, 2026

Jul 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 14, 2026

Jul 13, 2026

Why Is Ocugen (NASDAQ:OCGN) Back on the Penny Stock Radar? - Kalkine Media

Jul 13, 2026

Jul 13, 2026

Ocugen Signs $255M MENA Licensing Deal for OCU400 Gene Therapy to Treat Retinitis Pigmentosa - Minichart

Jul 13, 2026

Jul 13, 2026

Ocugen signs OCU400 MENA license agreement - grafa.com

Jul 13, 2026

Jul 13, 2026

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa - Ocugen, Inc.

Jul 13, 2026

Jul 13, 2026

Ocugen (OCGN) Secures Licensing Agreement for OCU400 in MENA Reg - GuruFocus

Jul 13, 2026

Jul 13, 2026

Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region - Moomoo

Jul 13, 2026

Jul 13, 2026

Ocugen (NASDAQ: OCGN) lines up OCU400 MENA license with $4M fees and 22% royalty - Stock Titan

Jul 13, 2026

Jul 13, 2026

Ocugen signs term sheet for OCU400 gene therapy in MENA region By Investing.com - Investing.com South Africa

Jul 13, 2026

Jul 13, 2026

Ocugen signs term sheet for OCU400 gene therapy in MENA region - Investing.com Nigeria

Jul 13, 2026

Jul 13, 2026

Ocugen Announces Binding Term Sheet for OCU400 License Deal in MENA Region with Roots Pharmaceutical - Quiver Quantitative

Jul 13, 2026

Jul 13, 2026

Gene therapy for inherited blindness set for MENA launch under Ocugen–Roots pact - Stock Titan

Jul 13, 2026

Jul 10, 2026

Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances - Yahoo Finance

Jul 10, 2026

Jul 10, 2026

Ocugen at Piper Sandler ophthalmology day: gene therapy push advances By Investing.com - Investing.com Canada

Jul 10, 2026

Jul 10, 2026

Ocugen at Piper Sandler ophthalmology day: gene therapy push advances - Investing.com

Jul 10, 2026

Jul 08, 2026

Ocugen’s Triple-Threat Pipeline: A $130M Cash Injection and a Summer of Make-or-Break Data - ad-hoc-news.de

Jul 08, 2026

Jul 07, 2026

Ocugen stock stays tied to pipeline progress. Nasdaq listing keeps the US angle clear. - Ad-hoc-news.de

Jul 07, 2026

Jul 02, 2026

Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch

Jul 02, 2026

Jul 01, 2026

Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch

Jul 01, 2026

Jul 01, 2026

Ocugen to Participate in Upcoming July Industry Conferences - The Manila Times

Jul 01, 2026